A detailed history of Persistent Asset Partners LTD transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Persistent Asset Partners LTD holds 17,520 shares of PTGX stock, worth $1.34 Million. This represents 0.72% of its overall portfolio holdings.

Number of Shares
17,520
Holding current value
$1.34 Million
% of portfolio
0.72%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 11, 2025

BUY
$40.89 - $56.37 $716,392 - $987,602
17,520 New
17,520 $968 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $3.76B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Persistent Asset Partners LTD Portfolio

Follow Persistent Asset Partners LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Persistent Asset Partners LTD, based on Form 13F filings with the SEC.

News

Stay updated on Persistent Asset Partners LTD with notifications on news.